Efficacy and Safety of Early Initiation of Butylphthalide Treatment in Patients With Acute Ischemic Stroke.

Korábbi kezelés

• Treatment with medications containing Butylphthalide following the onset of the current stroke episode;
• Concurrent malignancy or severe systemic disease with a life expectancy of less than 90 days;
• Participation in another interventional clinical study within the last 30 days before randomization, or currently participating in another interventional clinical study;

Más betegség

• Confirmed intracranial hemorrhage within the past 3 months, including intracerebral hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, and subdural/epidural hematoma;
• Presence of bradycardia (heart rate below 60 beats per minute) or sick sinus syndrome;
• History of drug or food allergies, including known allergies to the components of the study medication;
• Congenital or acquired hemorrhagic disorders, coagulation factor deficiencies, thrombocytopenia, or similar conditions;
• Severe psychiatric disorders or dementia that preclude understanding of informed consent or compliance with follow-up procedures;

Laborértékek

• Known severe hepatic or renal dysfunction or individuals undergoing dialysis for various reasons (severe hepatic dysfunction defined as ALT levels \>3 times the upper limit of normal or AST levels \>3 times the upper limit of normal; severe renal dysfunction defined as serum creatinine \>3.0 mg/dl [265.2 μmol/L] or glomerular filtration rate [GFR] \<30 ml/min/1.73m²);

Egyéb

• Systolic blood pressure \<90 mmHg or \>220 mmHg;
• Pregnant or breastfeeding individuals, or those planning to become pregnant within the next 90 days;
• Any other reason deemed by the investigator as unsuitable for participation in the study.

• Age between 18 and 80 years, gender not specified;
• Clinically diagnosed with acute ischemic stroke;
• Stroke onset within 3 hours;
• NIHSS score at enrollment between 4-25 points, with Item Ia ≤1 point;
• Pre-stroke mRS score ≤1 point;
• Participants and their representatives capable and willing to sign an informed consent form.